Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
TALK vs MNMD vs ATAI vs HIMS vs TDOC
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Pharmaceuticals
Medical - Equipment & Services
Medical - Healthcare Information Services
TALK vs MNMD vs ATAI vs HIMS vs TDOC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Medical - Pharmaceuticals | Medical - Equipment & Services | Medical - Healthcare Information Services |
| Market Cap | $868M | $2.04B | $964M | $6.63B | $1.26B |
| Revenue (TTM) | $229M | $0.00 | $3M | $2.35B | $2.51B |
| Net Income (TTM) | $8M | $-238M | $-154M | $128M | $-171M |
| Gross Margin | 43.0% | — | -259.1% | 69.7% | 65.6% |
| Operating Margin | 1.4% | — | -34.6% | 4.6% | -7.6% |
| Forward P/E | 38.2x | — | — | 51.5x | — |
| Total Debt | $0.00 | $0.00 | $25M | $1.12B | $1.04B |
| Cash & Equiv. | $37M | $258M | $18M | $229M | $781M |
TALK vs MNMD vs ATAI vs HIMS vs TDOC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Talkspace, Inc. (TALK) | 100 | 62.3 | -37.7% |
| Mind Medicine (Mind… (MNMD) | 100 | 36.5 | -63.5% |
| Atai Beckley N.V (ATAI) | 100 | 21.7 | -78.3% |
| Hims & Hers Health,… (HIMS) | 100 | 235.7 | +135.7% |
| Teladoc Health, Inc. (TDOC) | 100 | 4.2 | -95.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TALK vs MNMD vs ATAI vs HIMS vs TDOC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TALK is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- beta 0.86
- Beta 0.86, current ratio 6.38x
- Lower P/E (38.2x vs 51.5x)
- Beta 0.86 vs HIMS's 2.40
MNMD ranks third and is worth considering specifically for momentum.
- +214.0% vs HIMS's -51.0%
ATAI is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.48, Low D/E 21.2%, current ratio 3.21x
HIMS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 161.9% 10Y total return vs MNMD's 5.1%
- 59.0% revenue growth vs MNMD's -96.9%
- 5.5% margin vs ATAI's -51.1%
Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs MNMD's -96.9% | |
| Value | Lower P/E (38.2x vs 51.5x) | |
| Quality / Margins | 5.5% margin vs ATAI's -51.1% | |
| Stability / Safety | Beta 0.86 vs HIMS's 2.40 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +214.0% vs HIMS's -51.0% | |
| Efficiency (ROA) | 6.0% ROA vs MNMD's -70.7%, ROIC 10.7% vs -389.5% |
TALK vs MNMD vs ATAI vs HIMS vs TDOC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
TALK vs MNMD vs ATAI vs HIMS vs TDOC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HIMS leads in 2 of 6 categories
TDOC leads 1 • MNMD leads 1 • TALK leads 1 • ATAI leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
HIMS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TDOC and MNMD operate at a comparable scale, with $2.5B and $0 in trailing revenue. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to ATAI's -51.1%. On growth, ATAI holds the edge at +17.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $229M | $0 | $3M | $2.3B | $2.5B |
| EBITDAEarnings before interest/tax | $7M | -$191M | -$103M | $164M | $42M |
| Net IncomeAfter-tax profit | $8M | -$238M | -$154M | $128M | -$171M |
| Free Cash FlowCash after capex | -$2M | -$174M | -$90M | $73M | $251M |
| Gross MarginGross profit ÷ Revenue | +43.0% | — | -2.6% | +69.7% | +65.6% |
| Operating MarginEBIT ÷ Revenue | +1.4% | — | -34.6% | +4.6% | -7.6% |
| Net MarginNet income ÷ Revenue | +3.4% | — | -51.1% | +5.5% | -6.8% |
| FCF MarginFCF ÷ Revenue | -0.9% | — | -29.9% | +3.1% | +10.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.3% | — | +17.7% | +28.4% | -2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -163.0% | -75.0% | -27.3% | +32.1% |
Valuation Metrics
TDOC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 50.3x trailing earnings, HIMS trades at a 61% valuation discount to TALK's 129.5x P/E. On an enterprise value basis, TDOC's 15.1x EV/EBITDA is more attractive than TALK's 137.8x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $868M | $2.0B | $964M | $6.6B | $1.3B |
| Enterprise ValueMkt cap + debt − cash | $830M | $1.8B | $971M | $7.5B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | 129.50x | -10.04x | -4.31x | 50.32x | -6.11x |
| Forward P/EPrice ÷ next-FY EPS est. | 38.20x | — | — | 51.51x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 137.77x | — | — | 42.68x | 15.13x |
| Price / SalesMarket cap ÷ Revenue | 3.79x | — | 3130.37x | 2.82x | 0.50x |
| Price / BookPrice ÷ Book value/share | 7.69x | 5.56x | 5.51x | 12.25x | 0.89x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 89.61x | 4.40x |
Profitability & Efficiency
HIMS leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-102 for MNMD. ATAI carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), TALK scores 6/9 vs ATAI's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +6.9% | -102.5% | -96.4% | +23.7% | -12.4% |
| ROA (TTM)Return on assets | +5.9% | -70.7% | -64.3% | +6.0% | -5.9% |
| ROICReturn on invested capital | +3.9% | -3.9% | -45.0% | +10.7% | -11.5% |
| ROCEReturn on capital employed | +2.7% | -52.2% | -50.4% | +10.9% | -10.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 3 | 2 | 4 | 6 |
| Debt / EquityFinancial leverage | — | — | 0.21x | 2.07x | 0.75x |
| Net DebtTotal debt minus cash | -$37M | -$258M | $7M | $892M | $259M |
| Cash & Equiv.Liquid assets | $37M | $258M | $18M | $229M | $781M |
| Total DebtShort + long-term debt | $0 | $0 | $25M | $1.1B | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | — | -21.81x | -68.93x | — | -8.76x |
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $461 for TDOC. Over the past 12 months, MNMD leads with a +214.0% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs TDOC's -35.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +47.6% | +51.7% | +3.6% | -23.2% | -1.3% |
| 1-Year ReturnPast 12 months | +70.4% | +214.0% | +188.5% | -51.0% | +1.5% |
| 3-Year ReturnCumulative with dividends | +490.0% | +510.3% | +99.5% | +116.6% | -73.3% |
| 5-Year ReturnCumulative with dividends | -47.7% | -57.9% | -79.8% | +137.6% | -95.4% |
| 10-Year ReturnCumulative with dividends | -48.7% | +512.1% | -47.7% | +161.9% | -41.1% |
| CAGR (3Y)Annualised 3-year return | +80.7% | +82.7% | +25.9% | +29.4% | -35.6% |
Risk & Volatility
TALK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TALK is the less volatile stock with a 0.86 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.6% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.86x | 1.68x | 1.48x | 2.40x | 1.91x |
| 52-Week HighHighest price in past year | $5.20 | $21.09 | $6.75 | $70.43 | $9.77 |
| 52-Week LowLowest price in past year | $2.22 | $6.03 | $1.29 | $13.74 | $4.40 |
| % of 52W HighCurrent price vs 52-week peak | +99.6% | +98.1% | +59.4% | +36.4% | +71.2% |
| RSI (14)Momentum oscillator 0–100 | 62.7 | 64.9 | 51.5 | 54.5 | 74.1 |
| Avg Volume (50D)Average daily shares traded | 4.5M | 792K | 6.0M | 34.9M | 5.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: TALK as "Hold", MNMD as "Buy", ATAI as "Buy", HIMS as "Hold", TDOC as "Hold". Consensus price targets imply 199.3% upside for ATAI (target: $12) vs -3.3% for MNMD (target: $20).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $5.25 | $20.00 | $12.00 | $29.67 | $7.58 |
| # AnalystsCovering analysts | 10 | 1 | 4 | 19 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.0% | 0.0% | 0.0% | +1.4% | 0.0% |
HIMS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TDOC leads in 1 (Valuation Metrics).
TALK vs MNMD vs ATAI vs HIMS vs TDOC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is TALK or MNMD or ATAI or HIMS or TDOC a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -1. 9% for Atai Beckley N. V (ATAI). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Mind Medicine (MindMed) Inc. (MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TALK or MNMD or ATAI or HIMS or TDOC?
On trailing P/E, Hims & Hers Health, Inc.
(HIMS) is the cheapest at 50. 3x versus Talkspace, Inc. at 129. 5x. On forward P/E, Talkspace, Inc. is actually cheaper at 38. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — TALK or MNMD or ATAI or HIMS or TDOC?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -95. 4% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus TALK's -48. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TALK or MNMD or ATAI or HIMS or TDOC?
By beta (market sensitivity over 5 years), Talkspace, Inc.
(TALK) is the lower-risk stock at 0. 86β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 179% more volatile than TALK relative to the S&P 500. On balance sheet safety, Atai Beckley N. V (ATAI) carries a lower debt/equity ratio of 21% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — TALK or MNMD or ATAI or HIMS or TDOC?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -1. 9% for Atai Beckley N. V (ATAI). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TALK or MNMD or ATAI or HIMS or TDOC?
Hims & Hers Health, Inc.
(HIMS) is the more profitable company, earning 5. 5% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TALK or MNMD or ATAI or HIMS or TDOC more undervalued right now?
On forward earnings alone, Talkspace, Inc.
(TALK) trades at 38. 2x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 13. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATAI: 199. 3% to $12. 00.
08Which pays a better dividend — TALK or MNMD or ATAI or HIMS or TDOC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is TALK or MNMD or ATAI or HIMS or TDOC better for a retirement portfolio?
For long-horizon retirement investors, Talkspace, Inc.
(TALK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TALK: -48. 7%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TALK and MNMD and ATAI and HIMS and TDOC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TALK is a small-cap high-growth stock; MNMD is a small-cap quality compounder stock; ATAI is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.